Debt-to-equity in % of CNS Pharmaceuticals, Inc. from Q2 2020 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
CNS Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q2 2020 to Q3 2025.
  • CNS Pharmaceuticals, Inc. Debt-to-equity for the quarter ending September 30, 2025 was 21.5 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)

CNS Pharmaceuticals, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 21.5 +257 Sep 30, 2025
Q2 2025 32 +187 Jun 30, 2025
Q1 2025 99.5 +348 Mar 31, 2025
Q4 2024 2.41K +10.4K Dec 31, 2024
Q3 2024 -235 -372 -272% Sep 30, 2024
Q2 2024 -155 -220 -338% Jun 30, 2024
Q1 2024 -249 -286 -776% Mar 31, 2024
Q4 2023 -8K -8.02K -39680% Dec 31, 2023
Q3 2023 137 +122 +803% Sep 30, 2023
Q2 2023 65.1 +47.6 +271% Jun 30, 2023
Q1 2023 36.8 +17.9 +94.2% Mar 31, 2023
Q4 2022 20.2 -2.24 -9.98% Dec 31, 2022
Q3 2022 15.2 -2.04 -11.8% Sep 30, 2022
Q2 2022 17.5 +2.17 +14.1% Jun 30, 2022
Q1 2022 19 +4.38 +30% Mar 31, 2022
Q4 2021 22.4 +10.9 +93.8% Dec 31, 2021
Q3 2021 17.2 +10 +139% Sep 30, 2021
Q2 2021 15.3 +1.94 +14.5% Jun 30, 2021
Q1 2021 14.6 Mar 31, 2021
Q4 2020 11.6 Dec 31, 2020
Q3 2020 7.21 Sep 30, 2020
Q2 2020 13.4 Jun 30, 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.